Literature DB >> 16150942

KSHV G protein-coupled receptor inhibits lytic gene transcription in primary-effusion lymphoma cells via p21-mediated inhibition of Cdk2.

Mark Cannon1, Ethel Cesarman, Chris Boshoff.   

Abstract

Kaposi sarcoma (KS) remains the most common AIDS-associated malignancy worldwide. In sub-Saharan Africa especially, this aggressive endothelial-cell tumor is a cause of widespread morbidity and mortality. Infection with Kaposi sarcoma-associated herpesvirus (KSHV) is now known to be an etiologic force behind KS and primary-effusion lymphoma (PEL). Over time, KSHV has pirated many human genes whose products regulate angiogenesis, inflammation, and the cell cycle. One of these, the KSHV vGPCR, is a lytic product that is a constitutively active homolog of the IL-8 receptor. Although it is considered a viral oncogene and causes KS-like lesions in mice, vGPCR expression results in cell-cycle arrest of KSHV-infected PEL cells. In the present study, we show that this arrest is mediated by p21 in a p53-independent manner; the resulting Cdk2 inhibition decreases the efficiency of chemical induction of KSHV lytic transcripts ORF 50 and 26. Importantly, Cdk2 activity is also essential for replication in other human herpesviruses. The ability of vGPCR to delay or abort KSHV replication may explain how despite being a lytic product, this potent signaling molecule has a vital role in tumor formation via its induction of various KS-associated cytokines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16150942      PMCID: PMC1895347          DOI: 10.1182/blood-2005-06-2350

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  91 in total

Review 1.  Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity?

Authors:  F Neipel; J C Albrecht; B Fleckenstein
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

2.  Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).

Authors:  J J Russo; R A Bohenzky; M C Chien; J Chen; M Yan; D Maddalena; J P Parry; D Peruzzi; I S Edelman; Y Chang; P S Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

3.  Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication.

Authors:  W A Bresnahan; I Boldogh; P Chi; E A Thompson; T Albrecht
Journal:  Virology       Date:  1997-05-12       Impact factor: 3.616

4.  Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells.

Authors:  K A Staskus; W Zhong; K Gebhard; B Herndier; H Wang; R Renne; J Beneke; J Pudney; D J Anderson; D Ganem; A T Haase
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

5.  Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor.

Authors:  M M Rosenkilde; T W Schwartz
Journal:  Mol Pharmacol       Date:  2000-03       Impact factor: 4.436

6.  Charged residues at the intracellular boundary of transmembrane helices 2 and 3 independently affect constitutive activity of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.

Authors:  H H Ho; N Ganeshalingam; A Rosenhouse-Dantsker; R Osman; M C Gershengorn
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

7.  RBP-J (CSL) is essential for activation of the K14/vGPCR promoter of Kaposi's sarcoma-associated herpesvirus by the lytic switch protein RTA.

Authors:  Yuying Liang; Don Ganem
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Kaposi's sarcoma-associated herpesvirus (KSHV) chemokine vMIP-II and human SDF-1alpha inhibit signaling by KSHV G protein-coupled receptor.

Authors:  E Geras-Raaka; A Varma; I Clark-Lewis; M C Gershengorn
Journal:  Biochem Biophys Res Commun       Date:  1998-12-30       Impact factor: 3.575

9.  Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells.

Authors:  C Boshoff; T F Schulz; M M Kennedy; A K Graham; C Fisher; A Thomas; J O McGee; R A Weiss; J J O'Leary
Journal:  Nat Med       Date:  1995-12       Impact factor: 53.440

10.  Inhibition of constitutive signaling of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor by protein kinases in mammalian cells in culture.

Authors:  E Geras-Raaka; L Arvanitakis; C Bais; E Cesarman; E A Mesri; M C Gershengorn
Journal:  J Exp Med       Date:  1998-03-02       Impact factor: 14.307

View more
  21 in total

Review 1.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

2.  Cell membrane-bound Kaposi's sarcoma-associated herpesvirus-encoded glycoprotein B promotes virus latency by regulating expression of cellular Egr-1.

Authors:  Ossie F Dyson; Christopher M Traylen; Shaw M Akula
Journal:  J Biol Chem       Date:  2010-09-23       Impact factor: 5.157

Review 3.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

4.  NF-kappaB p50 plays distinct roles in the establishment and control of murine gammaherpesvirus 68 latency.

Authors:  Laurie T Krug; Christopher M Collins; Lisa M Gargano; Samuel H Speck
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

Review 5.  Herpesvirus-encoded GPCRs: neglected players in inflammatory and proliferative diseases?

Authors:  Henry F Vischer; Marco Siderius; Rob Leurs; Martine J Smit
Journal:  Nat Rev Drug Discov       Date:  2014-01-21       Impact factor: 84.694

6.  Convergence of Kaposi's sarcoma-associated herpesvirus reactivation with Epstein-Barr virus latency and cellular growth mediated by the notch signaling pathway in coinfected cells.

Authors:  Sophia Spadavecchia; Olga Gonzalez-Lopez; Kyla Driscoll Carroll; Diana Palmeri; David M Lukac
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

Review 7.  Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus.

Authors:  Dirk P Dittmer; Susan E Krown
Journal:  Curr Opin Oncol       Date:  2007-09       Impact factor: 3.645

8.  The phosphatase Shp2 is required for signaling by the Kaposi's sarcoma-associated herpesvirus viral GPCR in primary endothelial cells.

Authors:  Thomas Bakken; Meilan He; Mark L Cannon
Journal:  Virology       Date:  2009-12-09       Impact factor: 3.616

9.  Kaposi sarcoma-associated herpes virus (KSHV) G protein-coupled receptor (vGPCR) activates the ORF50 lytic switch promoter: a potential positive feedback loop for sustained ORF50 gene expression.

Authors:  Virginie Bottero; Neelam Sharma-Walia; Nagaraj Kerur; Arun George Paul; Sathish Sadagopan; Mark Cannon; Bala Chandran
Journal:  Virology       Date:  2009-07-28       Impact factor: 3.616

Review 10.  The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma.

Authors:  Leanne C Huysentruyt; Michael S McGrath
Journal:  J Leukoc Biol       Date:  2009-12-30       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.